Pharmaron, Inc.
Waltham, MA Phamaron Inc.
- UEI
- L8NQAFSTPSY9
- CAGE
- 4LFM9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 404 Wyman St #405, Waltham, MA 02451, USA
- Website
- pharmaron.com
- Employees
- 1K-5K
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Industrials
- Capital Goods
- Industrial Conglomerates
- Industrials & Manufacturing
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Ncats: service: mouse PK/PD study services for nnmt inhibitors: severable | Office of Logisitics and Acquisition Operations | $50,300 | |
| PK study in mice | National Center for Advancing Translational Sciences | $10,656 | |
| Pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of… | National Institute on Drug Abuse | $24,320 | |
| Pharmaron, INC.:1208250 [24-007232] | National Institute on Drug Abuse | $0 | |
| Testing of compounds in cardiac ION channel assays | National Institute on Drug Abuse | $78,300 |
About Pharmaron, Inc.
Pharmaron, Inc. is a global contract research organization (CRO) specializing in preclinical research services for pharmaceutical, biotechnology, and government agencies. Registered in SAM.gov since 2006, the company is a minority-owned, for-profit organization classified as a Subcontinent Asian (Asian-Indian) American owned business. The organization provides comprehensive drug discovery and development support, including pharmacokinetic assessments, toxicity studies, ion channel testing, and other critical research services that help advance potential new therapies through the drug development pipeline.
Through its federal contract awards, Pharmaron, Inc. has primarily worked with agencies within the National Institutes of Health (NIH), most notably the National Center for Advancing Translational Sciences (NCATS) and the National Institute on Drug Abuse (NIDA). The company's contract work has encompassed a wide range of scientific services, including pharmacokinetic studies in various animal models (mice, rats, dogs, and cynomolgus monkeys), cardiac ion channel testing, toxicity assessments, and evaluations of compounds related to metabolic disorders, dystonia, and potential therapeutic interventions. These contracts, consistently awarded as firm fixed-price purchase orders, typically range from $10,000 to $124,200 and do not involve small business set-asides. The research has spanned diverse scientific domains, including compound absorption, distribution, metabolism, and excretion (ADME) studies, maximally tolerated dose determinations, and comprehensive preclinical research to support drug development initiatives.
Regarding grant awards, Pharmaron, Inc. has at least one documented sub-grant award from Sanford Burnham Prebys Medical Discovery Institute. This sub-award involves a comprehensive research support package that includes detailed study recommendations for preclinical candidate nomination and investigational new drug (IND) submission. The scope of work for this sub-award encompasses multiple critical research components, including chemical manufacturing and controls (CMC), drug metabolism and pharmacokinetics (DMPK), safety assessment, Standard for Exchange of Nonclinical Data (SEND) compliance, and program management. The sub-award demonstrates Pharmaron's capability to provide end-to-end research support, from initial compound characterization through comprehensive safety and efficacy assessments, with a focus on preparing research data for potential regulatory submission.
Contract vehicles
Quick answers
What is Pharmaron, Inc.'s UEI?
Pharmaron, Inc.'s Unique Entity ID (UEI) in SAM.gov is L8NQAFSTPSY9.
What is Pharmaron, Inc.'s CAGE code?
Pharmaron, Inc.'s CAGE code is 4LFM9.
What is Pharmaron, Inc.'s primary NAICS code?
Pharmaron, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Pharmaron, Inc. located?
Pharmaron, Inc.'s physical address in SAM.gov is 404 Wyman St #405, Waltham, MA 02451, USA.
Is Pharmaron, Inc. registered in SAM.gov?
Yes. Pharmaron, Inc.'s SAM.gov registration is active through March 18, 2027.
Which contract vehicles does Pharmaron, Inc. hold?
Pharmaron, Inc. holds a place on 1 federal contract vehicle: NIH Bioanalysis Testing Services 2015-2020.
What is Pharmaron, Inc.'s most recent federal award?
Pharmaron, Inc.'s most recent federal contract award is Ncats: service: mouse PK/PD study services for nnmt inhibitors: severable (75N98026P01624), from Office of Logisitics and Acquisition Operations, on September 14, 2026.
On GovTribe
See Pharmaron, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors